OBJECTIVE -The vascular benefits of statins might be attenuated by inhibition of coenzyme Q 10 (CoQ 10 ) synthesis. We investigated whether oral CoQ 10 supplementation improves endothelial dysfunction in statin-treated type 2 diabetic patients.
ndothelial dysfunction portends diabetic vasculopathy. Endothelial dysfunction reflects increased vascular oxidative stress, whereby uncoupling of endothelial nitric oxide synthase activity and mitochondrial oxidative phosphorylation impairs the bioavailability and action of nitric oxide (1) .
Statins are widely used in diabetes management and can reduce cardiovascular events (2) . However, a proportion of statin-treated patients remain at risk of cardiovascular disease. Statins inhibit conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonate, but may thereby also decrease production of other intermediates in the cholesterol biosynthetic pathway, such as coenzyme Q 10 (CoQ 10 ) (3), an important intracellular antioxidant. We hypothesized that oral CoQ 10 supplementation would improve endothelial dysfunction in statin-treated type 2 diabetic patients.
RESEARCH DESIGN AND METHODS -We recruited type 2 diabetic patients aged 40 -79 years on stable-dose statin therapy for Ն6 weeks. Inclusion criteria were serum LDL cholesterol Ͻ2.5 mmol/l and endothelial dysfunction, defined as brachial artery flowmediated dilatation (FMD) Ͻ5.5%. Exclusions included use of antioxidant supplements or other lipid-regulating medications, GHb Ͼ8.5%, and blood pressure Ͼ150/90 mmHg.
Eligible subjects were assigned in a double-blind and randomized manner to oral CoQ 10 (200 mg/day) (Blackmores, Balgowlah, Australia) or placebo for 12 weeks. After a 4-week washout, participants crossed over to the alternate treatment. Brachial artery ultrasonography was performed, and fasting blood and 24-h urine samples were collected at the start and end of each treatment period. The Royal Perth Hospital Ethics Committee approved the study.
The brachial artery was imaged using a 12-MHz transducer connected to an Acuson Aspen ultrasound system (Siemens Medical Solutions, Malvern, PA), and FMD was measured as previously described (4). Endothelium-independent nitrate-mediated dilatation was measured following sublingual administration of glyceryl trinitrate (400 g). Ultrasound images were analyzed using semiautomated edge-detection software (5) .
Total cholesterol, triglycerides, and HDL cholesterol were determined by enzymatic methods, and LDL cholesterol was calculated using the Friedewald equation. GHb was measured using highperformance liquid chromatography. Plasma CoQ 10 was measured by reversephase high-performance liquid chromatography using electrochemical detection (interassay coefficient of variation 14%). Plasma F 2 -isoprostane and 24-h urinary 20-hydroxyeicosatetraenoic acid levels (markers of systemic oxidative stress) were measured by gas chromatographymass spectrometry (interassay coefficients of variation 5.6 and 10%, respectively) (6 -8).
Data were analyzed using SPSS 15.0 (Chicago, IL) and SAS 9.1 (Cary, NC). Plasma CoQ 10 data (skewed distribution) were logarithmically transformed for parametric analysis. Treatment effects were compared using mixed-effects models. Carryover effects were examined for and excluded.
RESULTS -Participants were typically middle-aged (mean Ϯ SD age 68 Ϯ 6 years) and overweight (BMI 29 Ϯ 4 kg/ m 2 ), with satisfactory control of glycemia (GHb 6.9 Ϯ 0.7%), blood pressure (systolic 123 Ϯ 14 mmHg and diastolic 65 Ϯ 7), and lipids (LDL cholesterol 1.8 Ϯ 0.3 mmol/l). Median duration of diabetes was 8 years. Seventy-eight percent of subjects had a history of hypertension, 48% had a history of stroke or coronary disease, and 26% had microvascular complications. Eighty-three percent of subjects were taking antihyperglycemic medication, most commonly metformin (78%); 52% were taking ACE inhibitors; 21% were taking angiotensin receptor blockers; and 65% were taking aspirin. Atorvastatin was the most commonly prescribed statin (52%), followed by simvastatin (35%) and pravastatin (13%).
Baseline brachial artery diameter was similar at all assessments and unaltered by CoQ 10 supplementation (Table 1 ). CoQ 10 increased brachial artery FMD by mean Ϯ SEM 1.0 Ϯ 0.5% (P ϭ 0.04) compared with placebo but did not alter nitrate-mediated dilatation (P ϭ 0.66). Absolute percent FMD pre-and postplacebo, pre-and postCoQ 10 , and change in percent FMD with placebo and CoQ 10 are shown in supplemental Figures A1, A2, and A3 (available in an online appendix at http://care.diabetes journals.org/cgi/content/full/dc08-1736/ DC1), re-spectively. Despite increasing plasma CoQ 10 levels 2.7-fold (P Ͻ 0.001), CoQ 10 supplementation did not alter plasma F 2 -isoprostane (P ϭ 0.58) or urinary 20-hydroxyeicosatetraenoic acid levels (P ϭ 0.28) or influence glycemia, blood pressure, or lipids (P Ͼ 0.05).
CONCLUSIONS -The new finding was that CoQ 10 supplementation improved endothelial dysfunction in statintreated type 2 diabetic patients, with no alteration in two markers of systemic oxidative stress. This is consistent with our previous study in statin-naive dyslipidemic type 2 diabetic patients in whom oral CoQ 10 also improved brachial artery FMD but did not alter plasma F 2 -isoprostane levels (4). However, a study in coronary heart disease patients (20% with diabetes and 80% statin-treated) showed that oral CoQ 10 increased both brachial artery FMD and endotheliumbound extracellular superoxide dismutase activity, suggesting that the beneficial effects on endothelial function are related to improvements in local vascular oxidative stress (9) . CoQ 10 could also decrease vascular oxidative stress by recoupling endothelial nitric oxide synthase and/or mitochondrial oxidative phosphorylation. The fact that plasma F 2 -isoprostane levels in our diabetic subjects were not significantly different from those in our previously studied nondiabetic control subjects (1,360 Ϯ 74 vs. 1,394 Ϯ 122 pmol/l, respectively; P ϭ 0.80) (4) probably reflects their satisfactory glycemic control; our results might have differed had we included patients with greater degrees of hyperglycemia and systemic oxidative stress. Whether CoQ 10 supplementation might improve endothelial function by modulating other vasoactive mediators, such as endothelin 1 (10) or asymmetric dimethylarginine, (11) merits further investigation.
Our statin-treated subjects had lower plasma CoQ 10 concentrations compared with those in the statin-naive dyslipidemic type 2 diabetic patients in our previous study (0.8 [0.2] vs. 1.3 [0.6] mol/l; P Ͻ 0.01) (4) . Although the lowering of plasma CoQ 10 concentrations with pravastatin therapy was not shown to predict cardiovascular outcomes in coronary patients (12), the effect of pravastatin (40 mg/day) on plasma CoQ 10 levels was modest (ϳ15% reduction vs. placebo) and inhibition of endogenous CoQ 10 production may be greater with higher doses of more potent statins (3). The patients in our study had endothelial dysfunction despite satisfactory control of blood pressure, glycemia, and lipids and may be representative of the proportion of statin-treated patients at increased residual risk of cardiovascular disease. Our absolute improvement in FMD of 1% with CoQ 10 supplementation may potentially translate to a 10 -25% reduction in residual cardiovascular risk in these patients (13, 14) . Impaired FMD is a consistent predictor of adverse cardiovascular events. Several interventions that improve FMD also improve cardiovascular outcomes (13) (14) (15) . The significance of the findings in our report, however, requires further investigation in a clinical end point trial.
